Ignite Creation Date:
2024-10-25 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06510283
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-15
Brief Title:
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDARAnti-LGI1 Encephalitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDARAnti-LGI1 Encephalitis
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractoryrecurrent anti-NMDAR and anti-LGI1 encephalitis
Through this prospective single-center open-label clinical trial we aim to investigate the effectiveness and safety of Telitacicept in refractoryrecurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment
Through this prospective single-center open-label clinical trial we aim to investigate the effectiveness and safety of Telitacicept in refractoryrecurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None